Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $62.50

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given a consensus recommendation of “Buy” by the nine research firms that are covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $62.50.

A number of research firms have recently commented on JSPR. Royal Bank of Canada dropped their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. UBS Group began coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 price objective for the company. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a report on Tuesday, March 11th.

Jasper Therapeutics Trading Down 1.9 %

Jasper Therapeutics stock opened at $5.21 on Monday. The stock has a market cap of $78.26 million, a PE ratio of -1.10 and a beta of 2.23. The stock has a 50-day moving average price of $5.79 and a 200 day moving average price of $15.30. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). On average, equities analysts predict that Jasper Therapeutics will post -4.47 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of JSPR. BNP Paribas Financial Markets boosted its holdings in Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. MetLife Investment Management LLC boosted its holdings in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares during the period. Wells Fargo & Company MN boosted its holdings in Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new position in Jasper Therapeutics in the 4th quarter worth approximately $223,000. Finally, Jane Street Group LLC purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $251,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.